• February 27, 2021

Caisson Biotech, LLC and Heparinex, LLC Announce Positive Examination Report of European Patent and the Discovery of a New Class of Sugar Polymers - Odessa American: Wire News

e-Edition Subscribe

Caisson Biotech, LLC and Heparinex, LLC Announce Positive Examination Report of European Patent and the Discovery of a New Class of Sugar Polymers

Font Size:
Default font size
Larger font size

Posted: Tuesday, February 23, 2021 6:00 am | Updated: 6:30 am, Tue Feb 23, 2021.

AUSTIN, Texas and OKLAHOMA CITY, Okla., Feb. 23, 2021 (SEND2PRESS NEWSWIRE) — Caisson Biotech and parent company Heparinex are pleased to announce that they have received a positive examination report from the European Patent Office for a patent covering the chemoenzymatic production of heparosan utilized in the HEPtune® drug delivery platform. Once certified, the new patent family will increase patent coverage across Europe, adding to the U.S. holdings.

The HEPtune platform, which utilizes heparosan, a naturally occurring polysaccharide, has been validated as a novel half-life extension and drug delivery alternative to commonly used polyethylene glycol (PEG). Unlike PEG, heparosan is naturally found in humans, is completely biodegradable, and will not trigger anaphylactic shock or anti-drug antibodies. The HEPtune platform has been applied to numerous drug classes including biologics, and small molecules via nanocarriers, including liposomes.

In addition to positive news received by the EPO, Heparinex is excited to announce that it has created a new class of sugar polymers, sulfated hepbiuronic acid (sHBA) that mimic some, but not all, of the desirable activities of heparin, a drug employed to treat many diseases including the fight against severe COVID-19 and influenza. These novel patent-pending drug candidates can quell the initiation of inflammation, but do not inhibit blood coagulation, thus can be used to protect organs such as the lungs, heart, and kidneys that are often damaged by the body’s own defenses during disease without the risk of bleeding. The sHBA should be a useful addition to the arsenal of drugs currently dispensed to treat hyper-inflammation spawned by infectious, cardiovascular, and auto-immune diseases.

Heparosan conjugation was developed by Presidential Professor Dr. Paul DeAngelis at the University of Oklahoma Health Sciences Center (OUHSC) and includes a robust U.S. and international patent portfolio. “Our goal is to decipher and harness the natural ‘sugar codes’ in the body in more selective, customized fashion to target diseases and reduce side effects. We are excited by the possibilities for better medicines”, said DeAngelis. He was named as one of the most influential researchers in the world according to a study led by an investigator at Stanford University and published in PLOS Biology.

About Caisson Biotech, LLC

Caisson Biotech, LLC is a collaboration driven biotechnology company specializing in the development of heparosan polymers to improve therapeutic drug delivery and performance. Caisson’s HEPtune® technology was invented by Chief Scientist and University of Oklahoma Professor Dr. Paul DeAngelis, a world renowned glycobiology and enzyme specialist. Visit: http://www.caissonbiotech.com/

Caisson Biotech is a subsidiary of Heparinex, LLC.

About Heparinex, LLC

Heparinex, LLC is a biopharmaceutical company focused on the novel recombinant synthesis of sugar-based compounds for markets including anticoagulation, inflammation, and cancer treatment. Dr. Paul DeAngelis originally discovered and patented Heparinex’s core technology platforms of proprietary carbohydrate production. Visit: https://heparinex.com/.

Heparinex and Caisson are funded and managed by Emergent Technologies, Inc. an innovation solutions and technology commercialization leader headquartered in Austin, Texas. Visit: http://www.emergenttechnologies.com/

*LOGO link for media: https://www.Send2Press.com/300dpi/21-0223s2p-caisson-logo-300dpi.jpg

NEWS SOURCE: Caisson Biotech LLC

This press release was issued on behalf of the news source (Caisson Biotech LLC) who is solely responsibile for its accuracy, by Send2Press® Newswire. Information is believed accurate but not guaranteed. Story ID: 68845 APDF-R8.2

© 2021 Send2Press®, a press release and e-marketing service of NEOTROPE®, Calif., USA.

To view the original version, visit: https://www.send2press.com/wire/caisson-biotech-llc-and-heparinex-llc-announce-positive-examination-report-of-european-patent-and-the-discovery-of-a-new-class-of-sugar-polymers/

Disclaimer: This press release content was not created by the Associated Press (AP).

© 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Odessa, TX

Current Conditions

Humidity: 63%
Winds: S at 7mph
Feels Like: 56°

Your Extended Forecast


High 77°/Low 49°
Mostly sunny. Highs in the upper 70s and lows in the upper 40s.


High 66°/Low 35°
Mix of sun and clouds. Highs in the mid 60s and lows in the mid 30s.


High 45°/Low 28°
Mostly cloudy. Highs in the mid 40s and lows in the upper 20s.


High 59°/Low 37°
Mainly sunny. Highs in the upper 50s and lows in the mid 30s.
Online Features

Pet Central


Having a pet is a lot of responsibility, and we’ll help by giving you lots of tips and tricks! More >>



Our fitness articles will help teach you how to work out with gym- and home-based exercises. More >>



Enjoy the crosswords challenge in our free daily puzzles, from the harder Sunday crossword to the quicker daily. More >>



Every Sudoku has a unique solution that can be reached logically. Enter numbers into the blank spaces so that each row, column and 3x3 box contains the numbers 1 to 9. More >>

  • ALL-ACCESS: Subscribe to our e-edition and premium website at myoaoa.com.
    You can read your daily newspaper without taking a walk to the driveway.
    Look back at yesterday's newspaper, or issues from months ago with our archive feature.
    Call circulation at 432-337-7314 to sign up today.